# Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Source: https://onco.cc/trials/nct04650451/  
OnCo record `nct04650451` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BPX-603 run by Bellicum Pharmaceuticals, suspended.

## Summary

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors is a phase 1 interventional study registered as NCT04650451 by Bellicum Pharmaceuticals, with 220 participants planned, started 2020-12-07. Conditions recorded: HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression and Solid Tumor, Adult. Interventions recorded: chimeric antigen receptor (CAR) T cell therapy.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04650451
- Phase: 1
- Setting: A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors
- Sponsor: Bellicum Pharmaceuticals
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT04650451: https://clinicaltrials.gov/study/NCT04650451

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [BPX-603](https://onco.cc/drugs/bpx-603/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct04650451.json